Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB) has been present in the human population since antiquity. Today over 2 billion people have been exposed. What can we learn form this remarkably resilient bacteria, and how do we address the formidable challenge of treating drug resistant strains? Dr. Jeffrey Cirillo, associate professor of microbial and molecular pathogenesis at the Texas A&M Health Science Center College of Medicine, examines tuberculosis from molecular to organ-specific levels and outlines the emergence of multidrug resistance across the world. Hosted by Dr. Mary Leuchars.
Addressing Tuberculosis and Multi-Drug Resistance at a Cellular Level

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB) has been present in the human population since antiquity. Today over 2 billion people have been exposed. What can we learn form this remarkably resilient bacteria, and how do we address the formidable challenge of treating drug resistant strains? Dr. Jeffrey Cirillo, associate professor of microbial and molecular pathogenesis at the Texas A&M Health Science Center College of Medicine, examines tuberculosis from molecular to organ-specific levels and outlines the emergence of multidrug resistance across the world. Hosted by Dr. Mary Leuchars.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Updates From the 7th World Symposium Task Force
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?